Private Placement

SAGA Metals' drill success and C$6M funding fuel a major critical mineral play in Labrador, aiming to secure North America's industrial future.

Aligos Therapeutics is using strategic stock grants to lure top talent. Is this a savvy growth play or a creeping cost for shareholders? We break it down.

A new 'inspired by' fragrance brand is betting its vertically integrated model and aggressive pricing can break the industry’s century-old luxury spell.

Centrus Energy is building a key Ohio facility, the first step in a multi-billion dollar plan to end US reliance on Russian uranium for next-gen reactors.

With a $2.5B boost from Blue Owl, Finance of America aims to move beyond reverse mortgages and reshape how millions of retirees access their home equity.

Brixton Metals secures nearly $10M in a complex financing deal. Here’s why this capital is a game-changer for its flagship Thorn copper-gold project.

Datavault AI is issuing a 'meme coin' to shareholders. Is this the future of corporate rewards or a regulatory tightrope walk with a speculative asset?

First Trust unveils its new Dividend Aristocrats Target Income ETF in Europe, blending stable dividend stocks with a covered call strategy for yield-seekers.

As the AI skills gap widens, a new framework aims to move companies from pilot purgatory to true adoption by training everyone, not just tech experts.

From a Greenland mine to a Romanian refinery, a tech breakthrough is de-risking a vital new source of rare earths for the West's defense and green tech.

A startup's breakthrough in GPS-denied warfare is redefining naval strategy and opening a new, complex frontier for strategic high-tech investment.

A new class of AI-driven blood tests can detect lung cancer recurrence years before imaging, shaking up patient care and the multi-billion dollar diagnostics market.

Adagio Medical lands ex-Medtronic exec Sean Salmon. His mission: drive its novel cryoablation tech to disrupt the competitive cardiac arrhythmia market.

Roivant Sciences reveals accelerated timelines for key drugs and a bold three-year growth plan, pivoting its unique 'Vant' model toward commercialization.

With leadership buying shares and promising trial data for its novel cancer drug, MAIA Biotechnology is sending strong signals to investors. What's next?

With a 2026 decision date set, Lifezone Metals is de-risking a world-class nickel project in Tanzania, promising to shake up the global battery supply chain.

With a new board chair and a clear shareholder mandate, Edgewater Wireless is shifting from R&D to monetizing its game-changing Spectrum Slicing tech.

Beyond the hype, one company's dual leadership award reveals the true engine of the GenAI revolution: a smarter, more powerful search foundation.

South Korean tobacco giant KT&G just earned a flawless 'AAA' ESG rating, a first for its industry. What does this mean for investors and sustainability?

After major setbacks, a surge of innovative drugs is set to transform the ALS market. We decode the science, the money, and what it means for patients.